胃泌素释放肽前体在小细胞肺癌诊断及预后的临床价值  

Clinical value of pro-gastrin-releasing peptide in diagnosis and prognosis of small-cell lung cancer

作　　者：张家祺（综述）[1] 王迎难（综述）[1] 李强（审校）[1] 

机构地区：[1]湖北省宜昌市第一人民医院呼吸内科,443000

出　　处：《国际肿瘤学杂志》2007年第3期216-218,共3页Journal of International Oncology

摘　　要：胃泌素释放肽前体（ProGRP）作为一种新的小细胞肺癌的肿瘤标志物，双抗体夹心酶联免疫吸附测定（ELISA）方法显示对小细胞肺癌诊断具有较高的敏感性和特异性。相比神经元特异烯醇化酶（NSE）更适宜用于小细胞肺癌的早期诊断。ProGRP在小细胞肺癌治疗与预后监测上也体现了优越性。临床研究发现，肾小球滤过率降低是假阳性的主要因素。临床上联合检测ProGRP和NSE，对小细胞肺癌的早期诊断、监测疗效及预后价值更大。Pro- gastrin- releasing peptide （ProGRP） is a new identified biomarker for small-cell lung cancer（SCLC）. A manual ELISA is developed for ProGRP measurement in serum. Serum levels of ProGRP are clearly related to the histological type of SCLC. Accumulative evidence shows that ProGRP is more sensitive and specific for the early stage SCLC than neuron-specific enolase （ NSE）, moreover, ProGRP also displays its superiority on staging, monitoring treatment and prognosis in patients with SCLC. Clinical researches demonstrate that impaired glomerular filtration tends to increase circulating levels of ProGRP and result in false negative. Combined detection of ProGRP and NSE has more value in early diagnosis, monitoring curative effect and prognosis of SCLC.

关 键 词：肺肿瘤 肿瘤标记 生物学 胃泌素释放肽 酶联免疫吸附测定 

分 类 号：R730.3[医药卫生—肿瘤] R392.11[医药卫生—临床医学]